Outpost24 Strengthens Global Brand Leadership with Appointment of Liz Drysdale as Chief Marketing Officer
15.10.2025 13:00:00 CEST | Business Wire | Press Release
Outpost24, a leader in exposure management and identity security, today announced the appointment of Liz Drysdale as Chief Marketing Officer (CMO). Liz brings over 25 years of international marketing experience, including a decade in cybersecurity, to drive Outpost24’s next phase of growth and global brand expansion.
Recognized by The Enterprise World Magazine as one of the “Most Influential Business Leaders to Watch in 2024,” Liz has a proven track record of building and scaling high-performing, multi-disciplinary teams. Her deep specialization lies in ensuring marketing functions are strategically aligned with sales and product engineering to accelerate business growth across global markets. Prior to joining Outpost24, she held senior leadership roles at market-defining cybersecurity pioneers, including SentinelOne, BeyondTrust, and CyberArk, where she drove successful go-to-market strategies for complex security portfolios.
At Outpost24, Liz will lead global marketing strategy, focusing on scaling brand impact and expanding market reach to reinforce the company’s position as a trusted partner in exposure management and identity security. Her mission involves overseeing all aspects of brand strategy, demand generation, product and channel marketing, specifically by translating Outpost24’s advanced technical capabilities into compelling value propositions that ensure customers and partners can effectively operationalize modern risk reduction practices.
“Liz’s appointment marks a pivotal step in strengthening our leadership team as we enter a new stage of growth,” said Ido Erlichman, CEO of Outpost24. “Her deep expertise in cybersecurity, combined with her passion for brand building and global go-to-market excellence, will be instrumental as we as we build a world-class executive team to continue to expand our platform, invest in innovation, and help customers transform how they identify, prioritize, and remediate risk.”
Liz’s appointment follows several key executive hires, including a new Chief Information Security Officer (CISO), Chief Technology Officer (CTO), and Chief Corporate Development Officer (CCDO), reinforcing Outpost24’s commitment to advancing its technology leadership, operational excellence, and strategic growth.
“Outpost24 has built an impressive reputation for helping organizations strengthen their cyber resilience across both digital and human attack surfaces,” said Liz Drysdale, CMO of Outpost24. “I’m excited to join a company that combines deep technical expertise with a customer-first mindset, delivering market-leading solutions that help businesses stay secure and confident in an ever-changing threat landscape.”
Backed by a dynamic executive team and a strong European presence, Outpost24 continues to solidify its position as a trusted partner for thousands of customers worldwide seeking to operationalize modern Exposure Management and Continuous Threat Exposure Management (CTEM) practices.
About Outpost24
Outpost24 is a leading provider of exposure management and identity security solutions. By combining its core Attack Surface Management platform with the identity and password security expertise of Specops, the company helps thousands of organizations worldwide proactively identify, manage, and reduce cyber risk across their entire digital and human attack surface. Founded in 2001 and headquartered in Sweden, Outpost24 has 12 additional offices worldwide, including in the US, UK, France, Belgium, and Spain. For more information, visit https://outpost24.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251015274656/en/
Contacts
Media Contact
Tila Pacheco
Eskenzi PR
tila@eskenzipr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom